These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9445619)

  • 1. [Prostate-specific antigen in cancer and benign prostatic hyperplasia].
    Kushlinskiĭ NE; Liubimova NV; Gorilovskiĭ LM
    Biull Eksp Biol Med; 1997 Sep; 124(9):327-30. PubMed ID: 9445619
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed].
    Bratt O; Björk T
    Lakartidningen; 2007 Nov 14-20; 104(46):3460-4. PubMed ID: 18072615
    [No Abstract]   [Full Text] [Related]  

  • 3. Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease.
    Shafer MW; Mangold L; Partin AW; Haab BB
    Prostate; 2007 Feb; 67(3):255-67. PubMed ID: 17192876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prostatic diseases: tumor markers (PAP and PSA) and age at risk].
    Manna A; Trasatti L; Cifaldi L; Marchei GG; Reale MG; Marchei P
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):91. PubMed ID: 1709213
    [No Abstract]   [Full Text] [Related]  

  • 5. [Insulin-like growth factor (IGF-1) and the clinical course of prostate cancer, benign hyperplasia and prostatic intraepithelial neoplasia].
    Povelitsa EA; Nabyrov EA
    Vopr Onkol; 2008; 54(5):596-601. PubMed ID: 19069473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Usefulness of free prostate specific antigen in the detection of prostate cancer].
    Azócar G; Castillo O; Van Cauwelaert R; Cumsille MA; Campero JM; Aguirre C; Wöhler C
    Rev Med Chil; 1999 Feb; 127(2):151-7. PubMed ID: 10436694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Present-day possibilities of prostate cancer screening in patients with benign prostatic hyperplasia before and after surgical treatment].
    Pushkar' DIu; Rasner PI; Skobelev PP
    Urologiia; 2001; (6):48-54. PubMed ID: 11785083
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
    Romppanen J; Haapalainen T; Punnonen K; Penttilä I
    Anticancer Res; 2002; 22(1A):415-20. PubMed ID: 12017325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
    J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [gamma-Seminoprotein (gamma-Sm)].
    Miyahara S
    Nihon Rinsho; 2010 Jul; 68 Suppl 7():743-6. PubMed ID: 20963907
    [No Abstract]   [Full Text] [Related]  

  • 14. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
    Lehrer S; Diamond EJ; Mamkine B; Droller MJ; Stone NN; Stock RG
    BJU Int; 2005 May; 95(7):961-2. PubMed ID: 15839913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients.
    Beneduce L; Prayer-Galetti T; Giustinian AM; Gallotta A; Betto G; Pagano F; Fassina G
    Cancer Detect Prev; 2007; 31(5):402-7. PubMed ID: 18035503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
    Maksimov VA; Kamalov AA; Karpov VK; Riaboĭ AV; Prokhorov AV
    Urologiia; 2001; (2):37-40. PubMed ID: 11490716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ductal adenocarcinoma of the prostate.
    Shazer RL; Luthringer D; Agus DB; Gross ME
    Clin Adv Hematol Oncol; 2004 Jun; 2(6):393-5; discussion 396. PubMed ID: 16163211
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Wymenga LF; Mensink HJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1733-8. PubMed ID: 10494319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
    Gao ZW; Liu G; Sheng BW
    Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.